Biospective is a specialty neuroscience CRO (preclinical & clinical) with leading expertise in rodent models to evaluate the efficacy of novel therapeutic agents. We are a one-stop shop providing a full range of preclinical services, including in-house model generation, housing, dosing, imaging, behavioral testing, and histology/IHC studies. We particularly excel in preclinical neuroscience studies involving mouse models of neurodegenerative, neuroinflammatory, demyelinating, and misfolded protein aggregation disorders.
Learn more about our validated and well-characterized mouse models of CNS diseases:
These in-house rodent models are readily available for your preclinical studies. We can also perform studies using commercially available or sponsor-provided models. Our Research & Development team is continually characterizing new models.
Please let us know your needs.
Biospective is a specialty neuroscience CRO (preclinical & clinical) with leading expertise in rodent models to evaluate the efficacy of novel therapeutic agents. We are a one-stop shop providing a full range of preclinical services, including in-house model generation, housing, dosing, imaging, behavioral testing, and histology/IHC studies. We particularly excel in preclinical neuroscience studies involving mouse models of neurodegenerative, neuroinflammatory, demyelinating, and misfolded protein aggregation disorders.
Learn more about our validated and well-characterized mouse models of CNS diseases:
These in-house rodent models are readily available for your preclinical studies. We can also perform studies using commercially available or sponsor-provided models. Our Research & Development team is continually characterizing new models.
Please let us know your needs.
Parkinson’s Disease Models (Alpha-Synuclein Models)
Biospective’s in vivo Parkinson’s disease mouse models rely on the inoculation of synthetic α-synuclein fibrils to initiate Parkinson’s disease-like Lewy bodies/Lewy neurites and transmit the pathology to anatomically-connected regions. These transgenic mice and α-synuclein fibril spreading PD models can mimic early “prodromal stage” or late “motor stage” of PD. Common injection sites include the striatum, the cerebral cortex, the substantia nigra, and the anterior olfactory nucleus (AON).
When synuclein is inoculated into the AON, the model shows neurodegeneration (which can be monitored longitudinally using in vivo MRI and neurofilament light biochemistry), as well as progressive changes in olfaction and sleep. This alpha-synuclein mouse model also shows neuronal loss and significant neuroinflammation by quantitative IHC.
ALS & FTLD (TDP-43)
Our rodent models of amyotrophic lateral sclerosis are transgenic TDP-43 models. Biospective’s TDP-43 mouse model is useful for studying amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). This model demonstrates regulatable brain neurodegeneration, spinal motor neuron loss, and muscle denervation, resulting in a progressive, neurodegenerative phenotype. We have developed a robust set of biomarkers for this model, including in vivo MRI, in vivo FDG PET imaging, motor assessments, and quantitative IHC.
Multiple Sclerosis Models (EAE Models and Cuprizone Models)
Biospective has both EAE and cuprizone demyelination/neuroinflammation multiple sclerosis mouse models. Biospective’s scientists work closely with sponsors to determine the most appropriate EAE and cuprizone models and associated biomarkers to assess therapies targeting demyelination and remyelination, inflammation, and neuroprotection.
Alzheimer’s Disease Models (Beta-Amyloid Models)
Biospective has an APP/PS1 transgenic model that demonstrates age-dependent beta-amyloid plaque pathology, astrogliosis, and microgliosis. This model is well-suited for assessment of a wide range of therapeutic agents for Alzheimer’s disease, including anti-amyloid therapies, neuroinflammatory modulators, and neuroprotective agents.
Contact Us
Let us know what you’re looking for. This form will be reviewed by our scientists.
©2023 Biospective Inc. | 1255 Peel, Suite #560, Montréal (Québec), Canada H3B 2T9 | info@biospective.com | 1-514-360-0141 | Privacy Notice | Sitemap